The Karnataka government is planning to tap the Central government's production-linked incentive (PLI) scheme to aggressively push for investments in the biopharmaceuticals and medical devices sector, C.N. Ashwath Narayan, Minister of Information Technology-Biotechnology, Higher Education and Science and Technology, said on Tuesday.
Participating in the 'Bioeconomy 2025 and Beyond' programme organised by the Association of Bioeconomy Led Enterprises (ABLE), Narayan said, "Bioeconomy of the state, which is currently valued at $24.4 billion contributing 33 per cent to the national share, is on course to achieve $50 billion value by 2025."
The bio-industrial segment comprising bio-renewables, bioenergy, biofuels, and green chemicals is expected to be the next big segment that can drive future growth. This segment has the potential to increase by four-fold in its contribution to the bioeconomy of the state from $1-2 billion to $6-7 billion, he said.
"The state government plans to attract investments in bio-agriculture (agriculture and animal husbandry) and bio-industrial (enzymes, biofuels, biomass, and green chemicals) industries as well to increase the share of bioeconomy. Research and development services, marine biotech and BioIT and informatics services will be the focus areas for the state of Karnataka over the next few years," Narayan said.
Stating that Karnataka is the third-largest producer of biofuels and among the states which reached 9 per cent blending of petrol in 2021, he added that the state's biotech industry has crossed $180 million in R&D spend.
As many as 95 biotech startups were set up in Karnataka in 2021, averaging almost eight startups every month, the minister stated.
Karnataka has emerged as the preferred destination for biotech investments in India, he said.
At present, the state hosts about 60 per cent of the biotech companies in the country and employs about 54 per cent of India's total biotech workforce, Narayan said.
--IANS
pvn/arm
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU